Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Extension Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera (THRIVE)

NCT06033586 is registered in ClinicalTrials.gov with Protagonist Therapeutics, Inc. as lead sponsor.

NCT NCT06033586
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06033586 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Extension Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera (THRIVE)
Lead sponsor
Protagonist Therapeutics, Inc.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
January 22, 2024
Completion date
April 1, 2027
Enrollment
46 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

polycythemia vera